drugset
drugset / Trial / NCT05441280

Pimavanserin for Insomnia in Veterans With PTSD

NCT05441280 ↗

Phase 2 Recruiting 60 enrolled VA Office of Research and Development
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a preliminary randomized, double-blind, placebo-controlled trial comparing pimavanserin 34mg at bedtime vs. placebo for the treatment of insomnia associated with post-traumatic stress disorder.

Timeline

Start
2023-12-28
Primary completion
2027-07-12
Completion
2027-07-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Pimavanserin Small molecule 34 mg Oral

Indications

insomnia post-traumatic stress disorder